Actinium reported data from the Phase III SIERRA trial of Iomab-B for relapsed or refractory acute myeloid leukaemia (r/r AML ...

Researchers used a novel approach to grow the crystals using only 5 micrograms of pure actinium—roughly one tenth the weight ...

PanTera, a Belgian radioisotope producer, announced today (11 September) that it had secured €93m ($102.4m) in an ...

Belgium-based PanTera has raised €134 million in a Series A funding round led by EQT Life Sciences to accelerate the ...

NEW YORK – Actinium Pharmaceuticals (NYSE:ATNM), Inc. (NYSE AMERICAN: ATNM) has shared results from its Phase 3 SIERRA trial for Iomab-B, a targeted radiotherapy aimed at conditioning patients ...

NEW YORK – Actinium Pharmaceuticals (NYSE:ATNM), Inc. (NYSE AMERICAN: ATNM) has shared results from its Phase 3 SIERRA trial for Iomab-B, a targeted radiotherapy aimed at conditioning patients for ...

Belgium-based PanTera has raised €134 million in a Series A funding round led by EQT Life Sciences to accelerate the large-scale production of actinium-225 (225Ac), a crucial isotope for Targeted ...

Now, Actinium is downgrading the priority of the ... which is intended for use as an induction and conditioning therapy for AML patients who need a bone marrow transplant. It consists of an ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today ...

On August 05, 2024, Actinium announced that after concluding both its clinical and Chemistry, Manufacturing and Controls ("CMC") interactions with the FDA regarding the BLA pathway for Iomab-B, the ...

The tools and techniques may have changed, but financial fraud is as pervasive as ever.